Transgenic mouse whose genome comprises an APP having a mutation at amino acid 664
US7544855B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Apr 23, 2004 |
| Grant date | Jun 9, 2009 |
| Priority date | — |
| Expiry date | Nov 23, 2024 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2800/2821
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
In accordance with the present invention, it is demonstrated that selected mutations such as an Asp->Ala (D664A) mutation in APP (which prevents cleavage at the caspase cleavage site) prevent both hippocampal synaptic loss and dentate gyral atrophy, even though such mutations do not interfere with the production of Aβ or the formation of amyloid plaques in a transgenic model of Alzheimer's disease. Accordingly, in view of this finding, methods have been developed for the identification of agents which block cleavage at Asp664 of APP, including transgenic animals which are useful for such purpose, as well as methods for the use thereof for the treatment of neurodegenerative diseases.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.